Xenon Pharmaceuticals Inc. (XENE) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update Transcript

Xenon Pharmaceuticals Inc. ( XENE ) Discusses Azetukalner NDA Submission for Focal Seizures and Psychiatry Program Update September 17, 2026 4:30 PM EDT Company Participants Colleen Alabiso - Senior Vice President of Corporate Affairs Ian Mortimer - President, CEO & Director Christopher Kenney - Chief Medical Officer Darren Cline - Chief Commercial Officer Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Matthew Barcus - Jefferies LLC, Research Division Luke Herrmann - Robert W. Baird & Co. Incorporated, Research Division Joseph Thome - TD Cowen, Research Division Nevin Varghese - RBC Capital Markets, Research Division Adithya Jayaraman - Evercore Inc. Presentation Operator Good day, everyone, and thank you for standing by. My name is Brilla, and I will be your conference operator today. At this time, I would like to welcome everyone to the Xenon Pharmaceuticals Conference Call. [Operator Instructions] I would now like to turn the call over to Colleen Alabiso, Senior Vice President of Corporate Affairs at Xenon. Please go ahead. Colleen Alabiso Senior Vice President of Corporate Affairs Thank you. Good afternoon. Thank you for joining us on our call and webcast to discuss the azetukalner NDA submission and psychiatry program update. Joining me today are Ian Mortimer, President and Chief Executive Officer; Dr. Chris Kenney, Chief Medical Officer; Darren Cline, Chief Commercial Officer; and Tucker Kelly, Chief Financial Officer. After completing our prepared remarks today, we will open the call for your questions. Please be advised that during this call, we will make a number of statements that are forward-looking within the meaning of applicable laws and regulations, including statements regarding the timing of and potential results from clinical studies, the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners' product candidates.